Evidence map›Paper›PMID 39667934›Full record

ArticleMolecular cell2024

CRL3

Roberta Cacioppo, Alexander Gillis, Iván Shlamovitz, Andrew Zeller, Daniela Castiblanco, Alastair Crisp, Benjamin Haworth, Angela Arabiotorre, Pegah Abyaneh, Yu Bao and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular cell, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Targeting CDKs in the RNAPII transcription cycle.Nature reviews. Drug discovery · 2026
    Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Roberta CacioppoDivision of Protein and Nucleic Acid Chemistry, MRC Laboratory of Molecular Biology, Cambridge CB2 0QH, UK.
Alexander GillisEMBL Australia Node in Single Molecule Science, University of New South Wales, Sydney, NSW, Australia; UNSW RNA Institute, University of New South Wales, Sydney, NSW, Australia; Department of Molecular Medicine, School of Biomedical Sciences, University of New South Wales, Sydney, NSW, Australia.
Iván ShlamovitzDivision of Protein and Nucleic Acid Chemistry, MRC Laboratory of Molecular Biology, Cambridge CB2 0QH, UK.
Andrew ZellerDivision of Protein and Nucleic Acid Chemistry, MRC Laboratory of Molecular Biology, Cambridge CB2 0QH, UK.
Daniela CastiblancoDivision of Protein and Nucleic Acid Chemistry, MRC Laboratory of Molecular Biology, Cambridge CB2 0QH, UK.
Alastair CrispDivision of Protein and Nucleic Acid Chemistry, MRC Laboratory of Molecular Biology, Cambridge CB2 0QH, UK.
Benjamin HaworthDivision of Protein and Nucleic Acid Chemistry, MRC Laboratory of Molecular Biology, Cambridge CB2 0QH, UK.
Angela ArabiotorreEMBL Australia Node in Single Molecule Science, University of New South Wales, Sydney, NSW, Australia; UNSW RNA Institute, University of New South Wales, Sydney, NSW, Australia; Department of Molecular Medicine, School of Biomedical Sciences, University of New South Wales, Sydney, NSW, Australia.
Pegah AbyanehDivision of Protein and Nucleic Acid Chemistry, MRC Laboratory of Molecular Biology, Cambridge CB2 0QH, UK.
Yu BaoDivision of Protein and Nucleic Acid Chemistry, MRC Laboratory of Molecular Biology, Cambridge CB2 0QH, UK.
Julian E SaleDivision of Protein and Nucleic Acid Chemistry, MRC Laboratory of Molecular Biology, Cambridge CB2 0QH, UK.
Scott BerryEMBL Australia Node in Single Molecule Science, University of New South Wales, Sydney, NSW, Australia; UNSW RNA Institute, University of New South Wales, Sydney, NSW, Australia; Department of Molecular Medicine, School of Biomedical Sciences, University of New South Wales, Sydney, NSW, Australia. Electronic address: scott.berry@unsw.edu.au.
Ana Tufegdžić VidakovićDivision of Protein and Nucleic Acid Chemistry, MRC Laboratory of Molecular Biology, Cambridge CB2 0QH, UK. Electronic address: atv@mrc-lmb.cam.ac.uk.

Funding

Medical Research Council MC_U105178808Medical Research Council MC_UP_1201/28
6 · The paper itself

Abstract

Control of RNA polymerase II (RNA Pol II) through ubiquitylation is essential for the DNA-damage response. Here, we reveal a distinct ubiquitylation pathway in human cells, mediated by CRL3

Indexed as

RNA Polymerase IITranscription, GeneticUbiquitinationUbiquitin-Protein LigasesCell ProliferationHEK293 CellsHeLa CellsHumansPhosphoprotein PhosphatasesPromoter Regions, GeneticTranscription Elongation, GeneticPhosphoprotein PhosphatasesRNA Polymerase IIUbiquitin-Protein LigasesARMC5CUL3elongationIntegratorINTS8pausingpromoter-proximalRNA polymerase IItranscriptionubiquitin

Identifiers

PMID39667934
PMCPMC7617427

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.